Which has higher valuation & earnings, ASND or GRFS?

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 17.09 -$258M $12.89 17.31 Grifols $8.51B 0.58 $454.82M $0.19 37.89

Does the media prefer ASND or GRFS?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat Ascendis Pharma A/S's score of 0.48 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMMT or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Summit Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -168.94% -141.92% Grifols 5.54% 6.21% 2.39%

Does the media refer more to SMMT or GRFS?

In the previous week, Summit Therapeutics had 6 more articles in the media than Grifols. MarketBeat recorded 10 mentions for Summit Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat Summit Therapeutics' score of 0.32 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, GRFS or BBIO?

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.58 $454.82M $0.19 37.89 BridgeBio Pharma $502.08M 25.58 -$724.93M -$3.57 N/A

Does the media favor GRFS or BBIO?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BridgeBio Pharma and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat BridgeBio Pharma's score of 0.53 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, EXEL or GRFS?

Exelixis has higher earnings, but lower revenue than Grifols. Exelixis is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.06 $782.57M $3.18 17.84 Grifols $8.51B 0.58 $454.82M $0.19 37.89

Is EXEL or GRFS more profitable?

Exelixis has a net margin of 35.33% compared to Grifols' net margin of 5.54%. Exelixis' return on equity of 42.17% beat Grifols' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Grifols 5.54% 6.21% 2.39%

Does the media prefer EXEL or GRFS?

In the previous week, Exelixis had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Exelixis and 4 mentions for Grifols. Exelixis' average media sentiment score of 0.90 beat Grifols' score of 0.60 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GRFS or BMRN?

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Grifols. MarketBeat recorded 7 mentions for BioMarin Pharmaceutical and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat BioMarin Pharmaceutical's score of 0.51 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Grifols (GRFS) Competitors

$7.20 -0.24 (-3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$7.20 0.00 (-0.07%)

As of 07:30 PM Eastern

Compare

GRFS vs. ASND, SMMT, BBIO, EXEL, and BMRN

Should you buy Grifols stock or one of its competitors? Grifols's main competitors and comparable companies include Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Grifols compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Ascendis Pharma A/S has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat Ascendis Pharma A/S's score of 0.48 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.09	-$258M	$12.89	17.31
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89

Ascendis Pharma A/S presently has a consensus price target of $310.75, suggesting a potential upside of 39.27%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 38.89%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ascendis Pharma A/S has a net margin of 70.99% compared to Grifols' net margin of 5.54%. Ascendis Pharma A/S's return on equity of 32.54% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Grifols	5.54%	6.21%	2.39%

Summary

Ascendis Pharma A/S beats Grifols on 11 of the 15 factors compared between the two stocks.

How does Grifols compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Grifols has a net margin of 5.54% compared to Summit Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Grifols	5.54%	6.21%	2.39%

In the previous week, Summit Therapeutics had 6 more articles in the media than Grifols. MarketBeat recorded 10 mentions for Summit Therapeutics and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat Summit Therapeutics' score of 0.32 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Grifols has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89

Summit Therapeutics presently has a consensus target price of $25.91, indicating a potential upside of 57.50%. Grifols has a consensus target price of $10.00, indicating a potential upside of 38.89%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Summit Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.41
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Grifols beats Summit Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Grifols compare to BridgeBio Pharma?

Grifols (NASDAQ:GRFS) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Grifols has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to BridgeBio Pharma's net margin of -97.03%. Grifols' return on equity of 6.21% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, BridgeBio Pharma had 6 more articles in the media than Grifols. MarketBeat recorded 10 mentions for BridgeBio Pharma and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat BridgeBio Pharma's score of 0.53 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.9% of BridgeBio Pharma shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Grifols has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89
BridgeBio Pharma	$502.08M	25.58	-$724.93M	-$3.57	N/A

Grifols currently has a consensus price target of $10.00, indicating a potential upside of 38.89%. BridgeBio Pharma has a consensus price target of $102.61, indicating a potential upside of 56.16%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Grifols on 8 of the 15 factors compared between the two stocks.

How does Grifols compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Exelixis has higher earnings, but lower revenue than Grifols. Exelixis is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.84
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89

85.3% of Exelixis shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Grifols' net margin of 5.54%. Exelixis' return on equity of 42.17% beat Grifols' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Grifols	5.54%	6.21%	2.39%

Exelixis presently has a consensus price target of $50.29, suggesting a potential downside of 11.36%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 38.89%. Given Grifols' higher probable upside, analysts clearly believe Grifols is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Exelixis had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Exelixis and 4 mentions for Grifols. Exelixis' average media sentiment score of 0.90 beat Grifols' score of 0.60 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Summary

Exelixis beats Grifols on 13 of the 17 factors compared between the two stocks.

How does Grifols compare to BioMarin Pharmaceutical?

Grifols (NASDAQ:GRFS) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Grifols presently has a consensus target price of $10.00, indicating a potential upside of 38.89%. BioMarin Pharmaceutical has a consensus target price of $89.17, indicating a potential upside of 43.34%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

Grifols has a net margin of 5.54% compared to BioMarin Pharmaceutical's net margin of 2.14%. Grifols' return on equity of 6.21% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Grifols. MarketBeat recorded 7 mentions for BioMarin Pharmaceutical and 4 mentions for Grifols. Grifols' average media sentiment score of 0.60 beat BioMarin Pharmaceutical's score of 0.51 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Grifols has higher revenue and earnings than BioMarin Pharmaceutical. Grifols is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.58	$454.82M	$0.19	37.89
BioMarin Pharmaceutical	$3.22B	3.74	$348.90M	$0.37	168.14

Summary

BioMarin Pharmaceutical beats Grifols on 11 of the 17 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRFS vs. The Competition

Export

Metric	Grifols	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.06B	$3.90B	$7.21B	$13.10B
Dividend Yield	1.15%	3.64%	2.53%	13.00%
P/E Ratio	37.89	13.95	274.58	25.69
Price / Sales	0.58	1,357.85	639.38	80.65
Price / Cash	5.25	109.50	76.31	52.02
Price / Book	0.57	15.30	10.44	6.32
Net Income	$454.82M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-2.70%	-0.22%	0.51%	1.35%
1 Month Performance	-10.00%	-6.06%	-3.38%	-3.68%
1 Year Performance	-26.90%	34.37%	16.04%	5.56%

Grifols Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRFS Grifols	4.7696 of 5 stars	$7.20 -3.2%	$10.00 +38.9%	-23.3%	$5.06B	$8.51B	37.89	25,247	High Trading Volume
ASND Ascendis Pharma A/S	4.5506 of 5 stars	$239.93 -9.4%	$310.80 +29.5%	+21.0%	$15.01B	$814.57M	18.67	1,189	Gap Down
SMMT Summit Therapeutics	2.5122 of 5 stars	$18.28 -0.8%	$25.91 +41.8%	-10.4%	$14.59B	N/A	N/A	265	Analyst Forecast
BBIO BridgeBio Pharma	3.3701 of 5 stars	$71.36 -1.4%	$102.61 +43.8%	+34.3%	$13.94B	$713.07M	N/A	839	Insider Trade
EXEL Exelixis	2.3428 of 5 stars	$55.30 -1.6%	$50.07 -9.5%	+46.9%	$13.70B	$2.44B	17.39	1,077

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRFS) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Grifols (GRFS) Competitors

GRFS vs. ASND, SMMT, BBIO, EXEL, and BMRN

How does Grifols compare to Ascendis Pharma A/S?

Summary

How does Grifols compare to Summit Therapeutics?

Summary

How does Grifols compare to BridgeBio Pharma?

Summary

How does Grifols compare to Exelixis?

Summary

How does Grifols compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Grifols (GRFS) Competitors

GRFS vs. ASND, SMMT, BBIO, EXEL, and BMRN

How does Grifols compare to Ascendis Pharma A/S?

Which has more risk & volatility, ASND or GRFS?

Does the media prefer ASND or GRFS?

Which has higher valuation & earnings, ASND or GRFS?

Do analysts rate ASND or GRFS?

Is ASND or GRFS more profitable?

Summary

How does Grifols compare to Summit Therapeutics?

Is SMMT or GRFS more profitable?

Does the media refer more to SMMT or GRFS?

Which has more risk and volatility, SMMT or GRFS?

Which has stronger valuation & earnings, SMMT or GRFS?

Do analysts recommend SMMT or GRFS?

Do institutionals & insiders believe in SMMT or GRFS?

Summary

How does Grifols compare to BridgeBio Pharma?

Which has more risk and volatility, GRFS or BBIO?

Is GRFS or BBIO more profitable?

Does the media favor GRFS or BBIO?

Do insiders & institutionals believe in GRFS or BBIO?

Which has higher earnings & valuation, GRFS or BBIO?

Do analysts prefer GRFS or BBIO?

Summary

How does Grifols compare to Exelixis?

Which has higher valuation and earnings, EXEL or GRFS?

Do institutionals & insiders have more ownership in EXEL or GRFS?

Is EXEL or GRFS more profitable?

Do analysts prefer EXEL or GRFS?

Does the media prefer EXEL or GRFS?

Which has more risk & volatility, EXEL or GRFS?

Summary

How does Grifols compare to BioMarin Pharmaceutical?

Do institutionals and insiders believe in GRFS or BMRN?

Do analysts recommend GRFS or BMRN?

Is GRFS or BMRN more profitable?

Does the media favor GRFS or BMRN?

Which has more risk & volatility, GRFS or BMRN?

Which has better valuation & earnings, GRFS or BMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRFS vs. The Competition

Grifols Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools